Center for Medical Device Evaluation, China Food and Drug Administration, Beijing, China.
Department of Medical Device Registration, China Food and Drug Administration, Beijing, , China.
J Biomed Mater Res B Appl Biomater. 2018 Aug;106(6):2093-2100. doi: 10.1002/jbm.b.34031. Epub 2017 Oct 28.
The 4th US-China Joint Workshop on Regulation, Standards and Innovation of Biomaterials was held during the Annual Meeting of the Society for Biomaterials on April 5, 2017 at Minneapolis, MN. This series of joint workshops have become a unique platform for both the US and China to discuss and update what is new in the field of biomaterials and medical devices in terms of regulation, standards and innovation since 2013. China Food and Drug Administration and its affiliated agencies such as Center for Medical Device Evaluation presented at each of the workshop. With the implementation of Regulations for the Supervision and Administration of Medical Devices (Decree of the State Council of the People's Republic of China, No. 650) since June 1, 2014, the regulatory changes and reform for medical devices in China have been hot topics in the workshops. This report captures the key information presented during the workshops, which includes major changes of the Chinese medical device regulation systems, reform of the review and approval system for medical devices in China, and the special procedures of review and approval for innovative medical devices. The market growth of medical devices along with demands for innovative technologies brings the ongoing regulatory changes and reform in China, which will certainly create positive impact on both the development of the Chinese healthcare system and the innovation of medical devices in China. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 2093-2100, 2018.
第四届中美生物材料法规、标准和创新联合研讨会于 2017 年 4 月 5 日在美国明尼苏达州明尼阿波利斯举行的生物材料学会年会上举行。自 2013 年以来,这一系列联合研讨会已成为中美双方讨论和更新生物材料和医疗器械领域法规、标准和创新最新情况的独特平台。中国食品药品监督管理局及其附属机构(如医疗器械审评中心)在每次研讨会上都有代表出席。自 2014 年 6 月 1 日起实施《医疗器械监督管理条例》(中华人民共和国国务院令第 650 号)以来,中国医疗器械监管的变化和改革一直是研讨会的热门话题。本报告介绍了研讨会期间介绍的关键信息,包括中国医疗器械监管体系的主要变化、中国医疗器械审评审批制度改革,以及创新医疗器械审评审批的特殊程序。医疗器械市场的增长以及对创新技术的需求带来了中国正在进行的监管变化和改革,这必将对中国医疗体系的发展和中国医疗器械的创新产生积极影响。© 2017 威利父子公司。J 生物医学材料研究杂志 B:应用生物材料,106B:2093-2100,2018 年。